Evonik Launches a Capsule Portfolio to Fast-Track Speed to Market for Oral Drug Products
Evonik has introduced the EUDRACAP, a portfolio of easy-to-handle capsules to fast-track speed to market for oral drug products in the early development stage.
Evonik announced on May 25, 2021 that it has launched EUDRACAP, a portfolio of easy-to-handle capsules to fast-track speed to market for oral drug products in the early development stage.
Using Evonik’s EUDRAGIT functional coatings to enhance the release profile of oral drug products, the new hydroxypropyl methyl cellulose-coated capsules work to protect sensitive active pharmaceutical ingredients from moisture and gastric acid, Evonik said in a company press release. The first product in the portfolio is an enteric coated capsule, which can can optimize gastric resistance, boost intestinal absorption, and enhance bioavailability.
In addition, the EUDRACAP Select line offers tailored contract development and manufacturing services, with a range of sizes, colors, and customized release profiles.
“With the help of EUDRACAP, we expect strong growth within our innovation growth field Healthcare Solutions,” said Paul Spencer, head of product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business line, in the press release. “EUDRACAP will foster our position as a fully integrated [contract development and manufacturing organization] along the entire pharmaceutical value chain.”
Source: Evonik
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
